The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.
Pilar Garrido Lopez
Honoraria - GlaxoSmithKline
Enriqueta Felip
Consultant or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Roche
Jean-Pierre Delord
No relevant relationships to disclose
Luis Paz-Ares
Honoraria - Pfizer
Juneko E. Grilley-Olson
Research Funding - Bayer; GlaxoSmithKline; Kyowa Hakko Kirin; Novartis; Peregrine Pharmaceuticals; ZIOPHARM Oncology
Michael S. Gordon
Research Funding - GlaxoSmithKline
Fabrice Barlesi
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Hendrik-Tobias Arkenau
No relevant relationships to disclose
Primo Lara
No relevant relationships to disclose
Paul K. Paik
No relevant relationships to disclose
Daniel Morgensztern
No relevant relationships to disclose
Shirish M. Gadgeel
No relevant relationships to disclose
Karen L. Reckamp
Research Funding - GlaxoSmithKline
Erin Marie Bertino
No relevant relationships to disclose
Sergey Orlov
No relevant relationships to disclose
Eugeny Levchenko
No relevant relationships to disclose
Ignacio Delgado
No relevant relationships to disclose
Jose Manuel Trigo Perez
No relevant relationships to disclose
Teresa Moran
No relevant relationships to disclose
Ulrik Niels Lassen
No relevant relationships to disclose